We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Exonate.
Exonate are developing a novel approach to modulating new vessel growth. By controlling the balance of two contrasting forms of a protein called Vascular Endothelial Growth Factor (VEGF), they have demonstrated that they could not only treat models of angiogenic disease (eg Cancer and wet AMD) but also protect kidney and nerve cells while simultaneously producing a pain killing effect.
The early research and development was undertaken in the Bristol MVRL laboratories of Professors David Bates and Steve Harper and continues in their laboratories in Bristol and Nottingham Universities and also in the laboratory of Associate Professor Jonathan Morris in the University of New South Wales in Sydney.
Exonate is now seeking to develop safer, more effective, therapies for the treatment of cancer and eye disease. The same approach will also allow the development of treatments for severe pain, and also the eye, nerve and kidney complications that occur in patients with diabetes. The Company has a pipeline of proprietary compounds that will be developed to address all of these therapeutic areas.